ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.
AP26113 has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
inhibitor | Acetylcholinesterase inhibitor | Selective serotonin reuptake inhibitor | Enzyme inhibitor | enzyme inhibitor | Metalloprotease inhibitor | Matrix metalloproteinase inhibitor | Inhibitor | Farnesyltransferase inhibitor | COX-2 inhibitor | ALK+ lymphoma | ALK inhibitor | ''ALK'' | ACE inhibitor |
He is also the first researcher who (in June 2010) successfully treated a patient affected by ALK+ lymphoma with an ALK inhibitor (crizotinib).